Suspension of trading

Spexis AG Share Price Swiss Exchange

Stocks

POLN

CH0106213793

Pharmaceuticals

OTC Markets Traded
Market Closed - Swiss Exchange 16:36:37 19/03/2025 GMT 5-day change 1st Jan Change
0.0100 CHF -75.00% Intraday chart for Spexis AG -75.00% -84.62%
3 months-82.46%
6 months-77.58%
1 week-75.00%
3 months-82.46%
6 months-77.58%
Current year-84.62%
1 week 0.01
Extreme 0.01
0.04
1 month 0.01
Extreme 0.01
0.06
3 years 0.01
Extreme 0.01
1.35
5 years 0.01
Extreme 0.01
9.45
Manager TitleAgeSince
Chief Executive Officer 64 30/03/2022
Director of Finance/CFO - 31/07/2024
Director TitleAgeSince
Chairman 70 19/11/2019
Director/Board Member 65 31/05/2013
Director/Board Member 80 29/12/2021
Change 5-day change 1-year change 3-year change Capi.($)
-75.00%-75.00%-88.89%-99.22% 817K
+2.06%+3.76%+21.48%-9.59% 64.39B
+0.74%+3.52%+51.88%+224.42% 56.12B
-3.10%+34.30%+34.30%+34.30% 40.54B
+1.13%+2.91%-51.49%-58.26% 37.98B
+6.97%+9.89%+71.34%-23.94% 31.89B
+12.59%+5.18%+147.68%-45.31% 26.69B
+5.78%+15.81%+66.37%+86.63% 22.73B
+7.52%+7.23%+3.06%+179.10% 16.66B
-0.81%+5.91%+63.81%+123.70% 16.6B
Average +3.65%+5.02%+31.95%+41.18% 34.84B
Weighted average by Cap. +2.85%+4.57%+40.07%+51.62%
Logo Spexis AG
Spexis AG, former Polyphor AG, is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of first-in-class molecules in oncology and antimicrobial resistance leveraging its macrocyclic peptide technology platform. The Company's medicines pipeline includes Balixafortide (POL6326), which is in a Phase III trial in combination with eribulin in patients with advanced breast cancer; Outer Membrane Protein Targeting Antibiotics (OMPTA), which is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis caused by Gram-negative bacteria; POL6014, which is an inhaled inhibitor of neutrophil elastase for the treatment of Cystic Fibrosis and other severe lung diseases, as well as Murepavadin (POL7080), which is an antibiotic with a mode of action to treat pseudomonas infections.
Employees
-
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B